Related Experiment Video
Updated: Oct 4, 2025
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Evaluation of the expressed miR-129 and miR-549a in patients with multiple sclerosis
Mina Montazeri1, Nahid Eskandari2, Reza Mansouri3
1Department of Immunology, International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Background:
The expression of microRNAs (miRNAs) as circulating biomarkers has been underlined in multiple sclerosis (MS) in the last decade. Due to the presence of a possible relationship between expressed miRNAs and heterogeneous appearances of the pathological processes in MS, the present study attempts to evaluate the expression of miR-129 and miR-549a in patients with MS in comparison with healthy control (HC) group.
Materials And Methods:
Peripheral blood mononuclear cells were separated from fifty patients with MS (subtypes including relapsing-remitting MS and secondary progressive MS) in the Kashani Hospital, Isfahan, Iran, and fifty people as HC group. After RNA extraction and complementary DNA synthesis, the expression of miR-129 and miR-549a was evaluated in patients with MS in comparison with the HC group using a quantitative real-time polymerase chain reaction assay. The data were analyzed using the Kolmogorov-Smirnov and Mann-Whitney tests. Spearman's correlation coefficient was used to examine the relationship between miR-129 and miR-549a with age.
Results:
The results showed that the expression of miR-129 and miR-549a was not significant in patients with MS in comparison with the HC group. Furthermore, the relationship between such miRNAs and age and gender was not significant.
Conclusion:
We suggest the expression of miR-129 and miR-549a as circulating miRNAs in peripheral blood mononuclear cells could not be considered a biomarker for diagnosis and Para clinical.
Insights
This study found no significant difference in miR-129 and miR-549a levels between multiple sclerosis (MS) patients and healthy controls. Therefore, these microRNAs are unlikely to be useful biomarkers for MS diagnosis.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Circulating microRNAs (miRNAs) are increasingly recognized as potential biomarkers.
- Multiple sclerosis (MS) exhibits heterogeneous pathological processes, suggesting a role for miRNAs.
- This study investigates specific miRNAs, miR-129 and miR-549a, in MS patients.
Purpose of the Study:
- To evaluate the expression levels of miR-129 and miR-549a in patients with multiple sclerosis (MS).
- To compare these miRNA levels with those in a healthy control (HC) group.
- To explore potential correlations between miRNA expression and patient age or gender.
Main Methods:
- Peripheral blood mononuclear cells were collected from 50 MS patients and 50 HC individuals.
- RNA extraction, cDNA synthesis, and quantitative real-time polymerase chain reaction were performed.
- Statistical analyses included Kolmogorov-Smirnov, Mann-Whitney tests, and Spearman's correlation.
Main Results:
- No significant difference in miR-129 and miR-549a expression was observed between MS patients and the HC group.
- No significant correlation was found between the expression of these miRNAs and the age or gender of the participants.
Conclusions:
- Circulating miR-129 and miR-549a in peripheral blood mononuclear cells do not appear to be reliable biomarkers for the diagnosis or paraclinical assessment of MS.
- Further research may be needed to identify other miRNA biomarkers for multiple sclerosis.
